📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-01 12:04
635 analysed today
635
Today
133,524
All-time analysed
40,118
Positive
6,284
Negative
79,305
Neutral
7,749
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
19 announcements match the current filters (relevance ≥ 5).
Sakar Secures 14 Oncology Product Approvals Across EU, UK & Canada with 7 Partners
Sakar Healthcare announced the receipt of 14 oncology product approvals in highly regulated markets including the EU, UK, and Canada across 7 business partners. Key partner Accord Healthcare received EMA approval for 5 site variations to Sakar's facility, bringing the total to 6 out of 8 initiated technology transfers. In addition, 3 products were approved for partners in the UK and Germany by MHRA/EMA, and 6 licensed-out products received Marketing Authorizations. These approvals expand commercialization reach into high-margin regulated oncology markets.
Confidence: HIGH
What changedSakar and its partners received regulatory clearances and site approvals for 14 oncology products across the EU, UK, and Canada.
Why it mattersUnlocks high-margin commercial manufacturing and licensing revenue in regulated markets, advancing Sakar's strategic pivot toward European and North American oncology supply.
Total product approvals: 14Business partners involved: 7Accord tech transfers completed: 6 of 8Licensed-out Marketing Authorizations: 6
📅 Short termPositive sentiment driver as regulatory clearances validate Sakar's EU GMP manufacturing compliance and partnership execution.
📈 Long termStrengthens Sakar's CDMO and licensing business model in regulated oncology markets, supporting margin expansion and management's long-term scale targets.
⚠ Risk flags
- Commercialization ramp-up timeline and off-take volumes depend on partner distribution execution
- Commercial value per approval not disclosed
Key Highlights
Received 14 oncology product approvals across the EU, UK, and Canada with 7 business partners
Partner Accord Healthcare secured EMA site variation approvals for 5 products, reaching 6 of 8 total tech transfers
MHRA and EMA approved 3 products for 2 UK partners and 1 German partner
Granted Marketing Authorizations for 6 licensed-out products (4 in EU, 1 in UK, 1 in Canada)
👀 What to Watch
Track the commercial rollout timeline and volume ramp-up for these 14 approved oncology products in upcoming quarterly revenue figures (TTM revenue: ₹272 Cr).
120% PAT Growth in Q1 FY27; Sakar Targets ₹1,000 Cr Revenue via Oncology Exports
Sakar Healthcare reported a robust Q1 FY27 with revenue growing 38% YoY to ₹72.97 Cr and PAT surging 120% to ₹10.28 Cr. The company is pivoting towards an oncology-led export model, having executed 65+ contracts and holding 33 ongoing tech transfer projects with major peers like Zydus and Torrent. Management maintains a long-term revenue target of ₹800-1,000 Cr from its EU-GMP Bavla facility, which currently has significant headroom. Backward integration with 21 in-house APIs is supporting a healthy 29% EBITDA margin.
Confidence: HIGH
What changedThe company has transitioned from a general pharma player to a specialized oncology-led export franchise with significant backward integration and EU-GMP certification.
Why it mattersHigh-margin oncology products and API integration provide a competitive moat and higher pricing power in regulated markets, potentially re-rating the business as it scales.
Q1 PAT Growth (YoY): 120%EBITDA Margin: 29%In-house Oncology APIs: 21Target Revenue vs TTM Revenue: ~397%Oncology Dossiers Submitted: 178
📅 Short termPositive sentiment is expected due to the sharp 120% PAT growth and margin expansion to 29% reported in the Q1 results.
📈 Long termStructural shift toward oncology exports and API integration could lead to significant growth if the ₹1,000 Cr revenue target is achieved by FY30.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Dependency on global marketing authorizations for 178 pending dossiers
- Regulatory compliance risks for the EU-GMP facility
- Client concentration among top 5-7 pharmaceutical partners
Key Highlights
Q1 FY27 PAT grew 120% YoY to ₹10.28 Cr on a 38% revenue increase to ₹72.97 Cr
Executed 65+ oncology product contracts and shared 261 dossiers globally during the quarter
33 ongoing oncology technology transfer projects with partners including Accord-Intas, Torrent, and Zydus
Management targets ₹800-1,000 Cr revenue at optimal utilization of the Bavla facility within 4-5 years
Domestic CMO business expected to double from ₹35 Cr in FY26 to approximately ₹70 Cr in FY27
👀 What to Watch
Monitor the conversion of 178 submitted dossiers into marketing authorizations and the ramp-up of the 33 tech transfer projects. Watch for margin sustainability as the revenue mix shifts further toward oncology exports.
Sakar Healthcare Q1 FY27 PAT Surges 120% YoY to ₹10.28 Cr on Oncology Scale-up
Sakar Healthcare reported a robust Q1 FY27 with revenue growing 38% YoY to ₹72.97 Cr, driven by its strategic shift toward the high-margin oncology segment. Profitability saw a significant jump as PAT rose 120% YoY to ₹10.28 Cr, while EBITDA margins expanded from 24% to 29% due to operating leverage. The company is aggressively expanding its global footprint, having executed over 65 oncology contracts and submitted 178 dossiers worldwide. With 33 technology transfer projects underway with major partners like Zydus and Torrent, the company is tracking toward its long-term revenue target of ₹1,000 Cr by FY30.
Confidence: HIGH
What changedThe company has successfully transitioned from a general contract manufacturer to a vertically integrated oncology specialist with EU-GMP certified facilities.
Why it mattersThe shift to oncology and regulated markets is structurally improving margins (now at 29%) and provides a scalable path to reach the management's ₹1,000 Cr revenue target by FY30.
Q1 FY27 Revenue: ₹72.97 CrYoY PAT Growth: 120%EBITDA Margin: 29%Oncology Contracts Executed: 65+Dossiers Submitted: 178Q1 Revenue vs TTM Revenue: 28.9%
📅 Short termThe stock is likely to react positively to the triple-digit PAT growth and significant margin expansion reported in this quarter.
📈 Long termThe company's focus on API-integrated oncology and partnerships with global majors like Accord Healthcare and Zydus positions it for sustained growth over the next 3-4 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Regulatory delays in dossier approvals
- High dependency on the oncology segment for margin maintenance
- Execution risks in complex technology transfer projects
Key Highlights
Revenue from operations grew 38% YoY to ₹72.97 Cr in Q1 FY27, representing ~29% of TTM revenue.
Net Profit (PAT) increased by 120% YoY to ₹10.28 Cr, supported by a 67% growth in EBITDA.
Executed 65+ oncology product contracts with 50+ commercial discussions currently in progress.
Submitted 178 dossiers globally with 16 Marketing Authorizations (MAs) already received.
Operating margins (EBITDA) improved to 29% from 24% in the previous year's corresponding quarter.
👀 What to Watch
Investors should monitor the conversion rate of the 50+ commercial discussions into active revenue and the progress of 33 technology transfer projects with MNC partners. The key regulatory milestone to watch is the approval of the remaining 162 submitted dossiers in regulated markets like the EU and UK.
120% PAT Growth in Q1 FY27; Sakar Healthcare Revenue Up 38% YoY to ₹72.97 Cr
Sakar Healthcare reported a strong Q1 FY27 with revenue growing 38% YoY to ₹72.97 Cr, driven by its oncology segment and new marketing authorizations. Profitability saw a significant jump, with PAT rising 120% to ₹10.28 Cr and EBITDA margins expanding by 500 bps to 29%. The company has executed over 65 oncology contracts and is currently managing 33 technology transfer projects with global partners like Accord-Intas and Zydus. Gross margins improved to 53% from 45% YoY, reflecting a shift towards higher-margin oncology products.
Confidence: HIGH
What changedSignificant improvement in margins and bottom-line growth compared to the same quarter last year, alongside increased regulatory filings and contract executions.
Why it mattersValidates the company's strategy of moving into high-margin oncology and API-integrated manufacturing, showing strong operating leverage as revenue scales.
Revenue (Q1 FY27): ₹72.97 CrPAT Growth (YoY): 120%EBITDA Margin: 29%Gross Margin: 53%Q1 Revenue vs TTM Revenue: ~29%
📅 Short termPositive reaction expected due to the sharp margin expansion and triple-digit PAT growth exceeding historical averages.
📈 Long termStructural shift towards specialized oncology and EU-GMP regulated markets supports a sustainable growth trajectory and improved margin profile over the coming years.
⚠ Risk flags
- Dependency on global regulatory approvals for 178 submitted dossiers
- Execution risk in complex technology transfer projects
Key Highlights
Revenue from operations grew 38% YoY to ₹72.97 Cr compared to ₹52.74 Cr in Q1 FY26.
Net Profit (PAT) surged 120% YoY to ₹10.28 Cr, up from ₹4.67 Cr.
EBITDA margins expanded to 29% from 24% in the previous year's quarter.
Executed more than 65 oncology product contracts and shared 261 dossiers globally.
33 technology transfer projects are currently underway with major partners like Torrent, Glenmark, and Zydus.
👀 What to Watch
Monitor the conversion of the 178 submitted dossiers into commercial marketing authorizations and the progress of the 33 technology transfer projects, as these are key drivers for the long-term revenue targets.
Sakar Healthcare Q1 FY27: Net Profit Jumps 120% YoY to ₹10.28 Cr
Sakar Healthcare reported a strong year-on-year performance for Q1 FY27, with revenue from operations growing 38.3% to ₹72.97 Cr compared to ₹52.74 Cr in Q1 FY26. Net profit surged 120% YoY to ₹10.28 Cr, driven by improved operating efficiencies and a likely shift toward higher-margin oncology products. However, on a sequential basis, net profit saw a slight decline of 6.7% from ₹11.02 Cr in the preceding March quarter. The company's EPS improved significantly to ₹4.62 from ₹2.11 in the year-ago period.
Confidence: HIGH
What changedThe company has delivered a significant year-on-year growth in both top-line and bottom-line for the first quarter of FY27, maintaining the momentum from FY26.
Why it mattersThe strong YoY growth validates Sakar's strategic focus on high-margin oncology products and EU GMP-certified manufacturing, which is essential for its premium positioning in regulated markets.
Revenue (Q1 FY27): ₹72.97 CrNet Profit (Q1 FY27): ₹10.28 CrYoY Profit Growth: 120%QoQ Revenue Growth: 2.6%EPS: ₹4.62
📅 Short termThe stock may see positive sentiment in the short term due to the robust YoY profit growth and margin expansion compared to the previous year.
📈 Long termThe structural shift toward oncology and API-integrated manufacturing provides a sustainable growth path, though reaching the ₹1,000 Cr revenue target by FY30 remains a long-term execution play.
⚠ Risk flags
- Sequential (QoQ) profit decline of 6.7%
- High dependency on global marketing authorizations for 80+ dossiers
- Increasing employee costs due to senior-level hiring
Key Highlights
Revenue from operations increased 38.3% YoY to ₹72.97 Cr from ₹52.74 Cr.
Net profit grew 120% YoY to ₹10.28 Cr from ₹4.67 Cr in the same quarter last year.
Earnings Per Share (EPS) rose to ₹4.62 compared to ₹2.11 in Q1 FY26.
Total expenses for the quarter stood at ₹59.94 Cr, with material costs at ₹40.04 Cr.
Board approved the appointment of Kashyap R. Mehta & Partners as Secretarial Auditors for a 5-year term.
👀 What to Watch
Investors should monitor the execution of the oncology injectable plant expansion and the progress of 80+ global dossier registrations, which are critical for the company's long-term revenue targets.
6.45% Stake Disclosed by Cobra India (Mauritius) Ltd in Sakar Healthcare
Cobra India (Mauritius) Limited has filed a disclosure under SEBI Takeover Regulations regarding its holding in Sakar Healthcare Limited. The entity, classified as a non-promoter, reported a holding of 1,469,571 shares, representing 6.4532% of the company's total voting capital. This filing confirms significant institutional interest from a foreign portfolio investor in the healthcare firm. The disclosure follows the requirements for substantial acquisition of shares under Regulation 29(1).
Confidence: HIGH
What changedA foreign institutional investor, Cobra India (Mauritius) Limited, has formally disclosed a substantial stake exceeding the 5% regulatory threshold in Sakar Healthcare.
Why it mattersInstitutional investment by foreign funds often provides a stamp of approval on a company's governance and growth potential, potentially improving market liquidity and valuation multiples for a small-cap stock.
Shares held by Acquirer: 1,469,571Percentage Stake: 6.4532%Acquirer Category: Non-Promoter
📅 Short termThe stock may see positive sentiment in the coming days as the market reacts to the presence of a significant foreign institutional shareholder.
📈 Long termLong-term impact depends on whether this institutional investor remains a stable shareholder and if the company can leverage this visibility to attract further capital or strategic partnerships.
⚠ Risk flags
- Concentration risk as a single foreign entity holds over 6%
- Potential for volatility if the institutional investor decides to exit
Key Highlights
Cobra India (Mauritius) Limited holds 1,469,571 equity shares in Sakar Healthcare.
The total stake amounts to 6.4532% of the total share and voting capital.
The acquirer is a non-promoter entity, indicating external institutional backing.
The disclosure was submitted in compliance with SEBI (SAST) Regulations, 2011.
👀 What to Watch
Investors should monitor the quarterly shareholding patterns to see if Cobra India or other institutional investors are increasing their stakes. This institutional presence is a positive signal for a small-cap company, but execution of business strategy remains the primary driver.
Sakar Healthcare FY26 Net Profit Jumps 74% to ₹30.48 Cr; Company Clarifies Financial Results
Sakar Healthcare Limited has reported a robust financial performance for the fiscal year ended March 31, 2026, with revenue from operations rising 41.7% to ₹251.74 crore. Net profit for the year surged by 74.2% to ₹30.48 crore, compared to ₹17.50 crore in the previous year. The company issued a clarification to the exchange regarding administrative formatting in its cash flow statements and auditor reports, confirming that all previously reported financial figures and the unmodified auditor's opinion remain unchanged. Additionally, the board has appointed new secretarial auditors to fill a casual vacancy.
Key Highlights
Annual Revenue from operations increased by 41.7% YoY to ₹25,173.60 lakh.
Net Profit for FY26 grew significantly to ₹3,048.46 lakh from ₹1,750.20 lakh in FY25.
Basic Earnings Per Share (EPS) improved to ₹13.70 in FY26 from ₹7.97 in FY25.
Total Assets expanded to ₹481.09 crore as of March 31, 2026, compared to ₹415.35 crore in the previous year.
The company confirmed no changes to financial data following a regulatory clarification request from the NSE.
👀 What to Watch
Investors should take confidence in the strong top-line and bottom-line growth and the management's prompt response to regulatory clarifications. The significant improvement in EPS and revenue suggests healthy business momentum in the pharmaceutical manufacturing segment.
Sakar Healthcare Q4 FY26 PAT Surges 91% YoY; Sets INR 380 Cr Revenue Target for FY27
Sakar Healthcare reported a robust 42% YoY revenue growth in Q4 FY26, reaching INR 71.10 crores, driven by the scaling of its oncology division. Profitability saw a significant surge with PAT increasing 91% YoY to INR 11.02 crores and EBITDA margins expanding to 37% for the quarter. The company has provided a strong growth guidance, aiming for INR 380 crores in revenue for FY27, representing approximately 40% growth. The oncology segment, which contributed 38% of FY26 revenue, is expected to be the primary growth driver through global partnerships and dossier approvals.
Key Highlights
Q4 FY26 PAT grew 91% YoY to INR 11.02 crores; EBITDA rose 67% to INR 26.24 crores.
Full-year FY26 revenue reached INR 251.74 crores, a 42% increase over the previous year.
Oncology division EBITDA margins are expected to remain in the 25%-30% range over the medium term.
The Bavla oncology facility has a peak revenue potential of INR 800-1,000 crores at full utilization.
Accord Healthcare partnership represents a potential revenue opportunity of INR 50-100 crores.
👀 What to Watch
Investors should monitor the execution of the oncology export strategy and the realization of the INR 380 crore revenue target for FY27. The high operating leverage in the oncology segment makes it a key driver for future margin expansion.
Sakar Healthcare Signs 40th Oncology Pact with Zydus; Expands EU Regulatory Footprint
Sakar Healthcare has reached a major milestone by signing its 40th global oncology agreement, partnering with Zydus Lifesciences for the GCC and emerging markets. The company is aggressively scaling its presence in the European Union with 23 Marketing Authorization (MA) filings and 33 site variations submitted for 18 cytotoxic molecules. Furthermore, Sakar is strengthening its backward integration with 21 in-house developed APIs, including 2 CEP approvals already secured. This transition towards an integrated, regulatory-led model is expected to enhance supply chain control and margin visibility.
Key Highlights
Signed 40th oncology agreement with Zydus Lifesciences for GCC and emerging markets
Filed 23 Marketing Authorizations in the EU, with 5 already secured in Bulgaria
Submitted 33 site variations for 18 cytotoxic molecules to EMA (EU) and MHRA (UK)
Developed 21 in-house APIs with 16 Written Confirmations and 2 CEP approvals secured
Strategic focus on high-entry-barrier oncology products and backward integration
👀 What to Watch
Investors should monitor the progress of the pending 18 EU Marketing Authorizations as they represent significant revenue potential. The company's focus on backward integration and partnerships with majors like Zydus makes it a strong candidate for long-term growth in the oncology segment.
Sakar Healthcare Q4FY26: Strategic Shift to High-Margin Oncology with 32 Molecules Ready for Launch
Sakar Healthcare is undergoing a major transformation into a vertically integrated oncology player, leveraging its new EU-GMP approved facility in Bavla, Gujarat. The company has developed 55 oncology molecules, with 32 ready for global launch and 12 Marketing Authorizations already secured in regulated markets. Management expects oncology products to deliver approximately 2x higher margins compared to general formulations. Additionally, the company is targeting a shift where own-brand exports will account for 70% of revenue, significantly enhancing overall profitability.
Key Highlights
EU-GMP approved oncology facility at Bavla provides integrated API and Finished Dosage Form (FDF) capabilities.
Pipeline of 55 oncology molecules developed in-house, with 32 ready for launch and 12 MAs already granted.
Annual production capacity includes 12.3 MT of APIs and 97 million tablets for oncology oral solids.
Strategic focus on own-brand exports (70% target) and high-margin oncology segments to drive value creation.
Global presence established in 60+ countries with 292+ product registrations and 300+ dossiers in process.
👀 What to Watch
Investors should track the commercial ramp-up of the 32 launch-ready oncology molecules, as these high-margin products are key to future earnings growth. The EU-GMP certification is a significant moat that facilitates entry into lucrative regulated markets.
Sakar Healthcare Q4 PAT Surges 91% YoY to ₹11 Cr; EBITDA Margins Expand to 37%
Sakar Healthcare reported a robust performance for Q4FY26, with revenue growing 42% YoY to ₹71.1 crore, driven by its oncology division and export momentum. Profitability saw a significant boost as PAT surged 91% to ₹11.02 crore, while EBITDA margins expanded by 600 basis points to 37%. The company has successfully submitted 125 oncology dossiers globally and is executing technology transfers with major pharma players like Zydus and Glenmark. Management expects FY27 to be a pivotal year as export volumes and oncology commercialization ramp up further.
Key Highlights
Q4FY26 Revenue grew 42% YoY to ₹7,109.70 Lakhs, while full-year FY26 revenue reached ₹25,173.60 Lakhs.
Q4 EBITDA jumped 67% YoY to ₹2,623.57 Lakhs with margins expanding from 31% to 37%.
Net Profit (PAT) for the quarter rose 91% YoY to ₹1,102.43 Lakhs, reflecting strong operating leverage.
Oncology division progress: 125 dossiers submitted globally with 12 marketing authorizations received to date.
Technology transfer projects are active with major firms including Accord-Intas, Torrent, and Zydus.
👀 What to Watch
The company is showing strong growth momentum in the high-margin oncology segment and significant margin expansion. Investors should monitor the conversion of the 125 submitted dossiers into commercial launches as a key catalyst for FY27.
Sakar Healthcare FY26 Net Profit Surges 74% to ₹30.48 Cr; Revenue Up 42% YoY
Sakar Healthcare reported a strong performance for the financial year ended March 31, 2026, with annual revenue growing 41.8% to ₹251.74 crore. Net profit for the full year saw a significant jump of 74.2%, reaching ₹30.48 crore compared to ₹17.50 crore in the previous year. The fourth quarter also showed robust growth, with revenue increasing 41.5% and net profit nearly doubling year-on-year. The company maintained an unmodified audit opinion and appointed new secretarial auditors to fill a casual vacancy.
Key Highlights
Annual Revenue from operations grew by 41.8% YoY to ₹25,173.60 lakh in FY26.
Full-year Net Profit increased by 74.2% to ₹3,048.46 lakh from ₹1,750.20 lakh in FY25.
Q4 FY26 Net Profit rose to ₹1,102.43 lakh, a 91.4% increase compared to ₹576.11 lakh in Q4 FY25.
Basic Earnings Per Share (EPS) improved significantly to ₹13.70 for FY26 from ₹7.97 in FY25.
Total Equity increased to ₹32,453.77 lakh as of March 31, 2026, from ₹28,556.11 lakh a year ago.
👀 What to Watch
The company is showing strong growth momentum in both top-line and bottom-line figures, suggesting a positive outlook. Investors should monitor the company's ability to maintain these margins as it scales its pharmaceutical manufacturing operations.
Sakar Healthcare Awarded Best Supplier by Ethiopian Pharmaceutical Supply Services for 2024-25
Sakar Healthcare Limited has been recognized as one of the best suppliers for the 2024-2025 period by the Ethiopian Pharmaceutical Supply Services (EPSS). This award acknowledges the company's excellence in fulfilling contractual commitments and maintaining a high standard of performance. The Director General of EPSS expressed intent to continue the partnership with new business and refill orders. This recognition validates Sakar's operational reliability in international markets and suggests a stable revenue pipeline from the Ethiopian region.
Key Highlights
Awarded 'Best Supplier' status by Ethiopian Pharmaceutical Supply Services (EPSS) for the year 2024-2025
Recognition based on excellence in fulfilling contractual commitments and remarkable performance
EPSS confirmed momentum for upcoming new business and refill orders for the company
Strengthens the company's reputation and footprint in the African pharmaceutical export market
👀 What to Watch
Investors should view this as a positive indicator of the company's export execution capabilities and international client retention. Monitor future financial results for growth in export revenue from the African region.
Sakar Healthcare Q3 FY26 PAT Surges 126% YoY to ₹10.25 Cr on Strong Oncology Growth
Sakar Healthcare reported a robust 62% YoY revenue growth to ₹70.34 crore for Q3 FY26, driven primarily by its high-margin oncology vertical. Net profit jumped 126% to ₹10.25 crore, supported by operational leverage and a shift toward own-brand exports which now contribute over 70% of revenue. The company has secured 11 marketing authorizations for oncology products in Europe and emerging markets, including Imatinib and Capecitabine. Management has provided a strong outlook, expecting 60-70% growth in the oncology segment for FY27 as more products enter commercialization in regulated markets.
Key Highlights
Revenue from operations grew 62% YoY to ₹70.34 crore in Q3 FY26.
Profit After Tax (PAT) increased by 126% YoY to ₹10.25 crore with EBITDA margins at 26%.
Oncology segment contributed ₹31 crore to Q3 revenue, with ₹19 crore derived from exports.
Received 11 marketing authorizations for oncology products; 10 molecules are currently in tech transfer with Intas/Accord for the EU market.
Management guides for a 60-70% year-on-year growth in the oncology vertical for FY27.
👀 What to Watch
Investors should closely track the commercialization of the 10 tech-transfer molecules with Intas/Accord, as these represent high-margin opportunities in the European market. The company's transition into a specialized oncology player with EU GMP certification makes it a strong growth candidate in the mid-cap pharma space.
Sakar Healthcare Pivots to High-Margin Oncology with EU-GMP Certified Facility
Sakar Healthcare is transitioning from a contract manufacturer to a vertically integrated oncology specialist with its EU-GMP certified facility in Bavla, Gujarat. The company has developed 55 oncology molecules, with 32 ready for global launch and 11 Marketing Authorizations already granted. Management highlights that oncology formulations offer approximately 2x higher margins compared to general formulations. The strategic roadmap focuses on increasing own-brand exports to 70% of revenue to enhance long-term profitability and brand equity.
Key Highlights
Developed 55 oncology molecules with 32 ready for launch and 11 Marketing Authorizations granted globally.
Oncology segment delivers approximately 2x higher margins versus general pharmaceutical formulations.
Annual production capacity includes 12.3 MT of APIs, 97 million tablets, and 13 million sterile injectable vials.
Strategic shift targeting 70% of revenue from own-brand exports across 60+ countries.
EU-GMP approved Bavla facility enables vertical integration from API to Finished Dosage Form (FDF).
👀 What to Watch
Investors should track the commercial rollout of the 32 launch-ready oncology molecules as they are key to margin expansion. The successful transition to a high-value oncology-led model could lead to a significant valuation re-rating.
Sakar Healthcare Q3 FY26 PAT Surges 126% YoY to ₹1,025 Lakhs; Revenue Up 62%
Sakar Healthcare reported a stellar Q3 FY26 with revenue growing 62% YoY to ₹7,034 lakhs, driven by its oncology division and EU market demand. Net profit more than doubled, rising 126% YoY to ₹1,025 lakhs, as PAT margins expanded significantly from 10% to 15%. The company's oncology facility received approval as a manufacturing source for Accord Healthcare UK, marking a major milestone for EU exports. With 11 marketing authorizations already secured and over 40 contract discussions ongoing, the company expects accelerated growth in FY27.
Key Highlights
Q3 FY26 Revenue grew 62% YoY to ₹7,034 lakhs, while 9M FY26 Revenue rose 42% to ₹18,064 lakhs
Net Profit (PAT) for the quarter surged 126% YoY to ₹1,025 lakhs with margins expanding from 10% to 15%
EBITDA increased 58% YoY to ₹1,859 lakhs, maintaining a healthy margin of 26%
Secured 11 Marketing Authorizations globally and completed over 50 business contracts for oncology products
Approved as a manufacturing source for Accord Healthcare UK for Imatinib supplies to the EU market
👀 What to Watch
Investors should view this as a strong growth signal, particularly the margin expansion and the breakthrough into the regulated EU oncology market. Monitor the progress of the 40+ ongoing contract discussions and the ramp-up of EU-linked supplies in FY27.
Sakar Healthcare Q3 FY26 Net Profit Surges 126% YoY to ₹10.25 Cr; Revenue Up 62%
Sakar Healthcare reported a stellar performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 62% YoY to ₹70.34 crore. Net profit for the quarter more than doubled, reaching ₹10.25 crore compared to ₹4.53 crore in the same period last year. The company's 9-month profit of ₹19.46 crore has already surpassed the full-year FY25 profit of ₹17.50 crore. Operating margins improved significantly, reflected in the EPS jumping from ₹2.08 to ₹4.59 YoY.
Key Highlights
Revenue from operations grew 62% YoY to ₹70.34 crore in Q3 FY26 compared to ₹43.42 crore in Q3 FY25.
Net Profit surged 126% YoY to ₹10.25 crore, with a strong sequential (QoQ) growth of 125%.
9M FY26 Net Profit reached ₹19.46 crore, already exceeding the entire FY25 full-year profit of ₹17.50 crore.
Basic EPS for the quarter increased significantly to ₹4.59 from ₹2.08 in the year-ago quarter.
Total expenses for the quarter stood at ₹59.90 crore, driven primarily by material costs of ₹38.54 crore.
👀 What to Watch
The company is exhibiting strong growth momentum and significant margin expansion. Investors should maintain a positive outlook while monitoring the sustainability of these growth rates in upcoming quarters.
Sakar Healthcare Q3 PAT Surges 126% YoY to ₹10.25 Cr; Revenue Up 62%
Sakar Healthcare reported a robust performance for Q3 FY2025-26, with revenue from operations growing 62% YoY to ₹70.34 crore. Net profit (PAT) saw a significant jump of 126% YoY, reaching ₹10.25 crore compared to ₹4.53 crore in the same quarter last year. On a sequential basis, PAT more than doubled from ₹4.54 crore in Q2 FY26, indicating strong operational momentum. The company's 9-month total income of ₹182.75 crore has already surpassed the full-year income of FY2024-25.
Key Highlights
Revenue from operations increased by 62% YoY to ₹7034.24 lakh from ₹4341.71 lakh.
Net Profit (PAT) surged by 126% YoY to ₹1024.91 lakh.
Profit Before Tax (PBT) grew by 100% YoY to ₹1095.25 lakh.
Basic EPS improved significantly to ₹4.59 from ₹2.08 in the previous year's quarter.
Total income for the 9-month period reached ₹182.75 crore, exceeding the full FY25 audited income of ₹178.90 crore.
👀 What to Watch
The company is demonstrating exceptional growth and margin expansion, with 9-month profits already exceeding previous full-year figures. Investors should consider this a strong growth play in the healthcare sector, though they should monitor the sustainability of these high margins in upcoming quarters.
Sakar Healthcare to Supply Imatinib (100mg & 400mg) to EU Market Following EMA Approval
Sakar Healthcare's oncology facility has been approved by the European Medical Agency (EMA) as a manufacturing source for Accord Healthcare's Imatinib (100mg and 400mg) tablets. This approval allows Sakar to cater to the European market, marking the first of nine oncology products planned under the Accord partnership. The company anticipates a positive impact on top-line sales in the upcoming fiscal year due to improved capacity utilization. Sakar is now positioned to supply a total of 12 approved products to international markets.
Key Highlights
EMA approval secured for manufacturing Imatinib 100mg and 400mg film-coated tablets for the EU market.
First of 9 oncology products to be manufactured for Accord Healthcare's European distribution.
Expected to drive top-line sales growth in the coming fiscal year through higher capacity utilization.
Sakar now has a portfolio of 12 approved products ready for overseas supply.
👀 What to Watch
Investors should view this as a significant milestone for Sakar's export business and monitor the revenue contribution from these EU supplies in upcoming quarterly results.
